Author:
Takano Hironobu,Tsuchikawa Takahiro,Nakamura Toru,Okamura Keisuke,Shichinohe Toshiaki,Hirano Satoshi
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Warshaw AL, Fernandez-del CC. Pancreatic carcinoma. N Engl J Med. 1992;326:455–65.
2. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer. 1995;31A(6):882–7.
3. Lygidakis NJ, Ziras FA, Kyparidou E, Parissis J, Papadopoulou P, Venetsanou B. Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma. Hepatogastroenterology. 1995;42(6):1039–52.
4. Sho M, Akahori T, Tanaka T, Kinoshita T, Tamamoto T, Nomi T, et al. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2012;20(2):197–205.
5. Strobel O, Berens V, Hinz U, Hartwig W, Hackert T, Bergmann F, et al. Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 2012;152:S33–42.